All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
| CAS Number | 1905409-39-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Related CD20 Products |
|---|
| Obinutuzumab
Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20. |
| Ofatumumab
Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation. |
| Rituximab
Rituximab is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM, MW: 143.86 KD. |
| Tositumomab
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. |
| Glofitamab
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
